^
    Back
    Association details:
    Biomarker:FGFR3 amplification
    Cancer:Gastric Adenocarcinoma
    Drug:Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Clin Case Rep
    Title:

    Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

    Published date:
    11/07/2021
    Excerpt:
    In the current study, we report a case of Gastric AD with FGFR3 gene amplification (10 copies), where treatment with Pazopanib in combination with Gemcitabine and Pemetrexed yielded partial response.
    Secondary therapy:
    gemcitabine + pemetrexed
    DOI:
    https://doi.org/10.1002/ccr3.4986